OncoMatch/Clinical Trials/NCT06140966
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Is NCT06140966 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for multiple myeloma.
Treatment: Daratumumab · Carfilzomib · Lenalidomide · Dexamethasone · Cisplatin · epirubicin · Cyclophosphamide · Etoposide · Melphalan · bortezomib — This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: WHSC1 t(4;14)
t(4;14)
Required: MAF t(14;16)
t(14;16)
Required: MAFB t(14;20)
t(14;20)
Required: CKS1B 1q21+
1q21+
Required: TP53 deletion
del(17p)
Required: TP53 mutation
p53 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: systemic therapy for multiple myeloma
Exception: Prior bisphosphonates and localized radiation are allowed.
Patients must be either untreated or have not received systemic MM therapy. Prior bisphosphonates and localized radiation are allowed.
Lab requirements
Blood counts
Platelet count ≥ 50,000/μL, absolute neutrophil count ≥ 1000/μL, haemoglobin ≥ 60 g/L before induction chemotherapy
Kidney function
Calculated creatinine clearance ≥ 30 mL/min
Liver function
ALT or AST ≤ 3x ULN; Bilirubin ≤ 2x ULN, except in participants with congenital bilirubinemia, such as Gilbert syndrome (direct bilirubin ≤ 2.0x ULN)
Cardiac function
Ejection fraction by echocardiogram (ECHO) ≥ 45%
Platelet count < 50,000/μL, absolute neutrophil count <1000/μL, and haemoglobin <60 g/L before induction chemotherapy. Calculated creatinine clearance <30 mL/min, alanine transaminase (ALT) or aspertate aminotransferase (AST) >3 times upper limit of normal (ULN). Bilirubin >2 times ULN, except in participants with congenital bilirubinemia, such as Gilbert syndrome (direct bilirubin >2.0 times ULN). Ejection fraction by echocardiogram (ECHO) ≥ 45%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06140966 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require WHSC1?
Yes, WHSC1 t(4;14) is a required biomarker for enrollment.
Does this trial require MAF?
Yes, MAF t(14;16) is a required biomarker for enrollment.
Does this trial require MAFB?
Yes, MAFB t(14;20) is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages